Patents by Inventor Timo EICHNER
Timo EICHNER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Epigenetic markers and related methods and means for the detection and management of certain cancers
Patent number: 11920200Abstract: The present invention relates to methods of determining the presence or absence of certain cancers in a human individual, as well as to related methods to determine the response to therapy against certain cancers in a human individual, in particular ovarian cancer in a woman. Such methods are based on the detection-from (eg cell-free) DNA of said human individual—of one or more methylated (or un-methylated) CpGs being associated with differentially methylated regions (DMRs) of the present invention; such as methylation (or un-methylation) at one or more or all of certain CpGs being associated with such DMRs. Accordingly, such methods have diagnostic, prognostic and/or predictive utility for detecting or managing certain cancers in women or men, in particular ovarian cancer in women.Type: GrantFiled: December 15, 2017Date of Patent: March 5, 2024Assignees: Eurofins Genomics Europe Sequencing GMBH, Genedata AG, UCL Business LTD.Inventors: Martin Widschwendter, Allison Jones, Iona Evans, Harri Lempiäinen, Johannes Eichner, Tamas Rujan, Timo Wittenberger, Tobias Paprotka, Benjamin Lindner -
Patent number: 11773147Abstract: The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.Type: GrantFiled: October 12, 2021Date of Patent: October 3, 2023Assignee: Pieris Pharmaceuticals GmbHInventors: Christine Rothe, Shane Olwill, Andrea Allersdorfer, Timo Eichner, Rachida Siham Bel Aiba, Marina Pavlidou
-
Publication number: 20230227568Abstract: The disclosure provides multimeric proteins comprising three, four, or more monomer polypeptides, each comprising a first 4-1BB-targeting moiety, an oligomerization moiety, and optionally a linker. The monomer polypeptide may further comprise one or more additional targeting moieties. The oligomerization moiety promotes the trimerization, tetramerization, or higher state of oligomerization of the monomer polypeptides. Such multimeric proteins can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators. The present disclosure also concerns methods of making the multimeric proteins described herein as well as compositions comprising such multimeric proteins. The present disclosure further relates to nucleic acid molecules encoding such multimeric proteins and methods for the generation of such multimeric proteins and nucleic acid molecules.Type: ApplicationFiled: June 4, 2021Publication date: July 20, 2023Inventors: Janet PEPER-GABRIEL, Josef PRASSLER, Timo EICHNER, Stefan GRUENER, Ahmed MOUSA, Shane OLWILL
-
Publication number: 20220098253Abstract: The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.Type: ApplicationFiled: October 12, 2021Publication date: March 31, 2022Inventors: Christine Rothe, Shane Olwill, Andrea Allersdorfer, Timo Eichner, Rachida Siham Bel Aiba, Marina Pavlidou
-
Patent number: 11168119Abstract: The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.Type: GrantFiled: January 18, 2018Date of Patent: November 9, 2021Assignee: PIERIS PHARMACEUTICALS GMBHInventors: Christine Rothe, Shane Olwill, Andrea Allersdorfer, Timo Eichner, Rachida Siham Bel Aiba, Marina Pavlidou
-
Patent number: 10927156Abstract: The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.Type: GrantFiled: October 30, 2019Date of Patent: February 23, 2021Assignee: Pieris Pharmaceuticals GmbHInventors: Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Rachida Siham Bel Aiba, Shane Olwill, Timo Eichner
-
Publication number: 20200048317Abstract: The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.Type: ApplicationFiled: October 30, 2019Publication date: February 13, 2020Inventors: Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Rachida Siham Bel Aiba, Shane Olwill, Timo Eichner
-
Patent number: 10501510Abstract: The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.Type: GrantFiled: July 15, 2016Date of Patent: December 10, 2019Assignee: Pieris Pharmaceuticals GmbHInventors: Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Rachida Siham Bel Aiba, Shane Olwill, Timo Eichner
-
Publication number: 20190345207Abstract: The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.Type: ApplicationFiled: January 18, 2018Publication date: November 14, 2019Inventors: Christine Rothe, Shane Olwill, Andrea Allersdorfer, Timo Eichner, Rachida Siham Bel Aiba, Marina Pavlidou
-
Publication number: 20190031729Abstract: The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.Type: ApplicationFiled: July 15, 2016Publication date: January 31, 2019Applicant: PIERIS PHARMACEUTICALS GMBHInventors: Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Rachida Siham BEL AIBA, Shane OLWILL, Timo EICHNER